Global Blood Cancer Drugs Market Growth 2020-2025

Publisher Name :
Date: 19-Nov-2020
No. of pages: 167

According to this study, over the next five years the Blood Cancer Drugs market will register a 10.4%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Blood Cancer Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Blood Cancer Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Blood Cancer Drugs, covering the supply chain analysis, impact assessment to the Blood Cancer Drugs market size growth rate in several scenarios, and the measures to be undertaken by Blood Cancer Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.

- Blood Chemotherapy Drugs

- Blood Targeted Therapy Drugs

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.

- Leukemia

- lymphoma

- Multiple Myeloma

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

- Americas

- United States

- Canada

- Mexico

- Brazil

- APAC

- China

- Japan

- Korea

- Southeast Asia

- India

- Australia

- Europe

- Germany

- France

- UK

- Italy

- Russia

- Middle East & Africa

- Egypt

- South Africa

- Israel

- Turkey

- GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

- Amgen,

- Novartis

- AstraZeneca PLC,

- Bayer AG,

- Bristol-Myers Squibb Company,

- Astellas Pharma,

- F.Hoffmann-La Roche,

- Celgene Corporation,

- Johnson & Johnson,

- Eli Lilly,

- Pfizer,

- AbbVie

- Takeda Pharmaceutical Company Ltd,

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

- To study and analyze the global Blood Cancer Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.

- To understand the structure of Blood Cancer Drugs market by identifying its various subsegments.

- Focuses on the key global Blood Cancer Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

- To analyze the Blood Cancer Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

- To project the consumption of Blood Cancer Drugs submarkets, with respect to key regions (along with their respective key countries).

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

- To strategically profile the key players and comprehensively analyze their growth strategies.

Global Blood Cancer Drugs Market Growth 2020-2025

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Blood Cancer Drugs Consumption 2015-2025
2.1.2 Blood Cancer Drugs Consumption CAGR by Region
2.2 Blood Cancer Drugs Segment by Type
2.2.1 Blood Chemotherapy Drugs
2.2.2 Blood Targeted Therapy Drugs
2.3 Blood Cancer Drugs Consumption by Type
2.3.1 Global Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Blood Cancer Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Blood Cancer Drugs Sale Price by Type (2015-2020)
2.4 Blood Cancer Drugs Segment by Application
2.4.1 Leukemia
2.4.2 lymphoma
2.4.3 Multiple Myeloma
2.5 Blood Cancer Drugs Consumption by Application
2.5.1 Global Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Blood Cancer Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Blood Cancer Drugs Sale Price by Type (2015-2020)

3 Global Blood Cancer Drugs by Company
3.1 Global Blood Cancer Drugs Sales Market Share by Company
3.1.1 Global Blood Cancer Drugs Sales by Company (2018-2020)
3.1.2 Global Blood Cancer Drugs Sales Market Share by Company (2018-2020)
3.2 Global Blood Cancer Drugs Revenue Market Share by Company
3.2.1 Global Blood Cancer Drugs Revenue by Company (2018-2020)
3.2.2 Global Blood Cancer Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Blood Cancer Drugs Sale Price by Company
3.4 Global Blood Cancer Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Blood Cancer Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Blood Cancer Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Blood Cancer Drugs by Regions
4.1 Blood Cancer Drugs by Regions
4.2 Americas Blood Cancer Drugs Consumption Growth
4.3 APAC Blood Cancer Drugs Consumption Growth
4.4 Europe Blood Cancer Drugs Consumption Growth
4.5 Middle East & Africa Blood Cancer Drugs Consumption Growth

5 Americas
5.1 Americas Blood Cancer Drugs Consumption by Countries
5.1.1 Americas Blood Cancer Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Blood Cancer Drugs Value by Countries (2015-2020)
5.2 Americas Blood Cancer Drugs Consumption by Type
5.3 Americas Blood Cancer Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Blood Cancer Drugs Consumption by Regions
6.1.1 APAC Blood Cancer Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Blood Cancer Drugs Value by Regions (2015-2020)
6.2 APAC Blood Cancer Drugs Consumption by Type
6.3 APAC Blood Cancer Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Blood Cancer Drugs by Countries
7.1.1 Europe Blood Cancer Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Blood Cancer Drugs Value by Countries (2015-2020)
7.2 Europe Blood Cancer Drugs Consumption by Type
7.3 Europe Blood Cancer Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Blood Cancer Drugs by Countries
8.1.1 Middle East & Africa Blood Cancer Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Blood Cancer Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Blood Cancer Drugs Consumption by Type
8.3 Middle East & Africa Blood Cancer Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Blood Cancer Drugs Distributors
10.3 Blood Cancer Drugs Customer

11 Global Blood Cancer Drugs Market Forecast
11.1 Global Blood Cancer Drugs Consumption Forecast (2021-2025)
11.2 Global Blood Cancer Drugs Forecast by Regions
11.2.1 Global Blood Cancer Drugs Forecast by Regions (2021-2025)
11.2.2 Global Blood Cancer Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Blood Cancer Drugs Forecast by Type
11.8 Global Blood Cancer Drugs Forecast by Application

12 Key Players Analysis
12.1 Amgen,
12.1.1 Company Information
12.1.2 Blood Cancer Drugs Product Offered
12.1.3 Amgen, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Amgen, Latest Developments
12.2 Novartis
12.2.1 Company Information
12.2.2 Blood Cancer Drugs Product Offered
12.2.3 Novartis Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Novartis Latest Developments
12.3 AstraZeneca PLC,
12.3.1 Company Information
12.3.2 Blood Cancer Drugs Product Offered
12.3.3 AstraZeneca PLC, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 AstraZeneca PLC, Latest Developments
12.4 Bayer AG,
12.4.1 Company Information
12.4.2 Blood Cancer Drugs Product Offered
12.4.3 Bayer AG, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Bayer AG, Latest Developments
12.5 Bristol-Myers Squibb Company,
12.5.1 Company Information
12.5.2 Blood Cancer Drugs Product Offered
12.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Bristol-Myers Squibb Company, Latest Developments
12.6 Astellas Pharma,
12.6.1 Company Information
12.6.2 Blood Cancer Drugs Product Offered
12.6.3 Astellas Pharma, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Astellas Pharma, Latest Developments
12.7 F.Hoffmann-La Roche,
12.7.1 Company Information
12.7.2 Blood Cancer Drugs Product Offered
12.7.3 F.Hoffmann-La Roche, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 F.Hoffmann-La Roche, Latest Developments
12.8 Celgene Corporation,
12.8.1 Company Information
12.8.2 Blood Cancer Drugs Product Offered
12.8.3 Celgene Corporation, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Celgene Corporation, Latest Developments
12.9 Johnson & Johnson,
12.9.1 Company Information
12.9.2 Blood Cancer Drugs Product Offered
12.9.3 Johnson & Johnson, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Johnson & Johnson, Latest Developments
12.10 Eli Lilly,
12.10.1 Company Information
12.10.2 Blood Cancer Drugs Product Offered
12.10.3 Eli Lilly, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Eli Lilly, Latest Developments
12.11 Pfizer,
12.11.1 Company Information
12.11.2 Blood Cancer Drugs Product Offered
12.11.3 Pfizer, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Pfizer, Latest Developments
12.12 AbbVie
12.12.1 Company Information
12.12.2 Blood Cancer Drugs Product Offered
12.12.3 AbbVie Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 AbbVie Latest Developments
12.13 Takeda Pharmaceutical Company Ltd,
12.13.1 Company Information
12.13.2 Blood Cancer Drugs Product Offered
12.13.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 Takeda Pharmaceutical Company Ltd, Latest Developments

13 Research Findings and Conclusion

List of Tables

Table 1. Research Methodology
Table 2. Data Source
Table 3. Blood Cancer Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Blood Chemotherapy Drugs
Table 5. Major Players of Blood Targeted Therapy Drugs
Table 6. Global Consumption Sales by Type (2015-2020)
Table 7. Global Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
Table 8. Global Blood Cancer Drugs Revenue by Type (2015-2020) ($ million)
Table 9. Global Blood Cancer Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 10. Global Blood Cancer Drugs Sale Price by Type (2015-2020)
Table 11. Global Consumption Sales by Application (2015-2020)
Table 12. Global Blood Cancer Drugs Consumption Market Share by Application (2015-2020)
Table 13. Global Blood Cancer Drugs Value by Application (2015-2020)
Table 14. Global Blood Cancer Drugs Value Market Share by Application (2015-2020)
Table 15. Global Blood Cancer Drugs Sale Price by Application (2015-2020)
Table 16. Global Blood Cancer Drugs Sales by Company (2017-2019) (K Units)
Table 17. Global Blood Cancer Drugs Sales Market Share by Company (2017-2019)
Table 18. Global Blood Cancer Drugs Revenue by Company (2017-2019) ($ Millions)
Table 19. Global Blood Cancer Drugs Revenue Market Share by Company (2017-2019)
Table 20. Global Blood Cancer Drugs Sale Price by Company (2017-2019)
Table 21. Global Blood Cancer Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 22. Players Blood Cancer Drugs Products Offered
Table 23. Blood Cancer Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 24. Global Blood Cancer Drugs Consumption by Regions 2015-2020 (K Units)
Table 25. Global Blood Cancer Drugs Consumption Market Share by Regions 2015-2020
Table 26. Global Blood Cancer Drugs Value by Regions 2015-2020 ($ Millions)
Table 27. Global Blood Cancer Drugs Value Market Share by Regions 2015-2020
Table 28. Americas Blood Cancer Drugs Consumption by Countries (2015-2020) (K Units)
Table 29. Americas Blood Cancer Drugs Consumption Market Share by Countries (2015-2020)
Table 30. Americas Blood Cancer Drugs Value by Countries (2015-2020) ($ Millions)
Table 31. Americas Blood Cancer Drugs Value Market Share by Countries (2015-2020)
Table 32. Americas Blood Cancer Drugs Consumption by Type (2015-2020) (K Units)
Table 33. Americas Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
Table 34. Americas Blood Cancer Drugs Consumption by Application (2015-2020) (K Units)
Table 35. Americas Blood Cancer Drugs Consumption Market Share by Application (2015-2020)
Table 36. APAC Blood Cancer Drugs Consumption by Regions (2015-2020) (K Units)
Table 37. APAC Blood Cancer Drugs Consumption Market Share by Regions (2015-2020)
Table 38. APAC Blood Cancer Drugs Value by Regions (2015-2020) ($ Millions)
Table 39. APAC Blood Cancer Drugs Value Market Share by Regions (2015-2020)
Table 40. APAC Blood Cancer Drugs Consumption by Type (2015-2020) (K Units)
Table 41. APAC Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
Table 42. APAC Blood Cancer Drugs Consumption by Application (2015-2020) (K Units)
Table 43. APAC Blood Cancer Drugs Consumption Market Share by Application (2015-2020)
Table 44. Europe Blood Cancer Drugs Consumption by Countries (2015-2020) (K Units)
Table 45. Europe Blood Cancer Drugs Consumption Market Share by Countries (2015-2020)
Table 46. Europe Blood Cancer Drugs Value by Countries (2015-2020) ($ Millions)
Table 47. Europe Blood Cancer Drugs Value Market Share by Countries (2015-2020)
Table 48. Europe Blood Cancer Drugs Consumption by Type (2015-2020) (K Units)
Table 49. Europe Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
Table 50. Europe Blood Cancer Drugs Consumption by Application (2015-2020) (K Units)
Table 51. Europe Blood Cancer Drugs Consumption Market Share by Application (2015-2020)
Table 52. Middle East & Africa Blood Cancer Drugs Consumption by Countries (2015-2020) (K Units)
Table 53. Middle East & Africa Blood Cancer Drugs Consumption Market Share by Countries (2015-2020)
Table 54. Middle East & Africa Blood Cancer Drugs Value by Countries (2015-2020) ($ Millions)
Table 55. Middle East & Africa Blood Cancer Drugs Value Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Blood Cancer Drugs Consumption by Type (2015-2020) (K Units)
Table 57. Middle East & Africa Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
Table 58. Middle East & Africa Blood Cancer Drugs Consumption by Application (2015-2020) (K Units)
Table 59. Middle East & Africa Blood Cancer Drugs Consumption Market Share by Application (2015-2020)
Table 60. Blood Cancer Drugs Distributors List
Table 61. Blood Cancer Drugs Customer List
Table 62. Global Blood Cancer Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 63. Global Blood Cancer Drugs Consumption Market Forecast by Regions
Table 64. Global Blood Cancer Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 65. Global Blood Cancer Drugs Value Market Share Forecast by Regions
Table 66. Global Blood Cancer Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 67. Global Blood Cancer Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 68. Global Blood Cancer Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 69. Global Blood Cancer Drugs Value Market Share Forecast by Type (2021-2025)
Table 70. Global Blood Cancer Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 71. Global Blood Cancer Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 72. Global Blood Cancer Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 73. Global Blood Cancer Drugs Value Market Share Forecast by Application (2021-2025)
Table 74. Amgen, Product Offered
Table 75. Amgen, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 76. Amgen, Main Business
Table 77. Amgen, Latest Developments
Table 78. Amgen, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis Product Offered
Table 80. Novartis Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 81. Novartis Main Business
Table 82. Novartis Latest Developments
Table 83. Novartis Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca PLC, Product Offered
Table 85. AstraZeneca PLC, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 86. AstraZeneca PLC, Main Business
Table 87. AstraZeneca PLC, Latest Developments
Table 88. AstraZeneca PLC, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Bayer AG, Product Offered
Table 90. Bayer AG, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 91. Bayer AG, Main Business
Table 92. Bayer AG, Latest Developments
Table 93. Bayer AG, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Bristol-Myers Squibb Company, Product Offered
Table 95. Bristol-Myers Squibb Company, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 96. Bristol-Myers Squibb Company, Main Business
Table 97. Bristol-Myers Squibb Company, Latest Developments
Table 98. Bristol-Myers Squibb Company, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Astellas Pharma, Product Offered
Table 100. Astellas Pharma, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 101. Astellas Pharma, Main Business
Table 102. Astellas Pharma, Latest Developments
Table 103. Astellas Pharma, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. F.Hoffmann-La Roche, Product Offered
Table 105. F.Hoffmann-La Roche, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. F.Hoffmann-La Roche, Main Business
Table 107. F.Hoffmann-La Roche, Latest Developments
Table 108. F.Hoffmann-La Roche, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 109. Celgene Corporation, Product Offered
Table 110. Celgene Corporation, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 111. Celgene Corporation, Main Business
Table 112. Celgene Corporation, Latest Developments
Table 113. Celgene Corporation, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Johnson & Johnson, Product Offered
Table 115. Johnson & Johnson, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 116. Johnson & Johnson, Main Business
Table 117. Johnson & Johnson, Latest Developments
Table 118. Johnson & Johnson, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Eli Lilly, Product Offered
Table 120. Eli Lilly, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 121. Eli Lilly, Main Business
Table 122. Eli Lilly, Latest Developments
Table 123. Eli Lilly, Basic Information, Company Total Revenue (in $ million), Blood Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Pfizer, Product Offered
Table 125. Pfizer, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 126. Pfizer, Main Business
Table 127. Pfizer, Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 128. Pfizer, Latest Developments
Table 129. AbbVie Product Offered
Table 130. AbbVie Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 131. AbbVie Main Business
Table 132. AbbVie Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 133. AbbVie Latest Developments
Table 134. Takeda Pharmaceutical Company Ltd, Product Offered
Table 135. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 136. Takeda Pharmaceutical Company Ltd, Main Business
Table 137. Takeda Pharmaceutical Company Ltd, Latest Developments
Table 138. Takeda Pharmaceutical Company Ltd, Basic Information, Manufacturing Base, Sales Area and Its Competitors

List of Figures

Figure 1. Picture of Blood Cancer Drugs
Figure 2. Blood Cancer Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Blood Cancer Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Blood Cancer Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Blood Chemotherapy Drugs
Figure 7. Product Picture of Blood Targeted Therapy Drugs
Figure 8. Global Blood Cancer Drugs Consumption Market Share by Type (2015-2020)
Figure 9. Global Blood Cancer Drugs Value Market Share by Type (2015-2020)
Figure 10. Blood Cancer Drugs Consumed in Leukemia
Figure 11. Global Blood Cancer Drugs Market: Leukemia (2015-2020) (K Units)
Figure 12. Global Blood Cancer Drugs Market: Leukemia (2015-2020) ($ Millions)
Figure 13. Blood Cancer Drugs Consumed in lymphoma
Figure 14. Global Blood Cancer Drugs Market: lymphoma (2015-2020) (K Units)
Figure 15. Global Blood Cancer Drugs Market: lymphoma (2015-2020) ($ Millions)
Figure 16. Blood Cancer Drugs Consumed in Multiple Myeloma
Figure 17. Global Blood Cancer Drugs Market: Multiple Myeloma (2015-2020) (K Units)
Figure 18. Global Blood Cancer Drugs Market: Multiple Myeloma (2015-2020) ($ Millions)
Figure 19. Global Blood Cancer Drugs Consumption Market Share by Application (2015-2020)
Figure 20. Global Blood Cancer Drugs Value Market Share by Application (2015-2020)
Figure 21. Global Blood Cancer Drugs Sales Market Share by Company in 2017
Figure 22. Global Blood Cancer Drugs Sales Market Share by Company in 2019
Figure 23. Global Blood Cancer Drugs Revenue Market Share by Company in 2017
Figure 24. Global Blood Cancer Drugs Revenue Market Share by Company in 2019
Figure 25. Global Blood Cancer Drugs Sale Price by Company in 2019
Figure 26. Global Blood Cancer Drugs Consumption Market Share by Regions 2015-2020
Figure 27. Global Blood Cancer Drugs Value Market Share by Regions 2015-2020
Figure 28. Americas Blood Cancer Drugs Consumption 2015-2020 (K Units)
Figure 29. Americas Blood Cancer Drugs Value 2015-2020 ($ Millions)
Figure 30. APAC Blood Cancer Drugs Consumption 2015-2020 (K Units)
Figure 31. APAC Blood Cancer Drugs Value 2015-2020 ($ Millions)
Figure 32. Europe Blood Cancer Drugs Consumption 2015-2020 (K Units)
Figure 33. Europe Blood Cancer Drugs Value 2015-2020 ($ Millions)
Figure 34. Middle East & Africa Blood Cancer Drugs Consumption 2015-2020 (K Units)
Figure 35. Middle East & Africa Blood Cancer Drugs Value 2015-2020 ($ Millions)
Figure 36. Americas Blood Cancer Drugs Consumption Market Share by Countries in 2019
Figure 37. Americas Blood Cancer Drugs Value Market Share by Countries in 2019
Figure 38. Americas Blood Cancer Drugs Consumption Market Share by Type in 2019
Figure 39. Americas Blood Cancer Drugs Consumption Market Share by Application in 2019
Figure 40. United States Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 41. United States Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 42. Canada Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 43. Canada Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 44. Mexico Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 45. Mexico Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. APAC Blood Cancer Drugs Consumption Market Share by Countries in 2019
Figure 47. APAC Blood Cancer Drugs Value Market Share by Regions in 2019
Figure 48. APAC Blood Cancer Drugs Consumption Market Share by Type in 2019
Figure 49. APAC Blood Cancer Drugs Consumption Market Share by Application in 2019
Figure 50. China Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 51. China Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 52. Japan Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 53. Japan Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 54. Korea Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. Korea Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Southeast Asia Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Southeast Asia Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. India Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 59. India Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. Australia Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 61. Australia Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. Europe Blood Cancer Drugs Consumption Market Share by Countries in 2019
Figure 63. Europe Blood Cancer Drugs Value Market Share by Countries in 2019
Figure 64. Europe Blood Cancer Drugs Consumption Market Share by Type in 2019
Figure 65. Europe Blood Cancer Drugs Consumption Market Share by Application in 2019
Figure 66. Germany Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 67. Germany Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 68. France Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 69. France Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 70. UK Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. UK Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. Italy Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. Italy Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. Russia Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 75. Russia Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Middle East & Africa Blood Cancer Drugs Consumption Market Share by Countries in 2019
Figure 77. Middle East & Africa Blood Cancer Drugs Value Market Share by Countries in 2019
Figure 78. Middle East & Africa Blood Cancer Drugs Consumption Market Share by Type in 2019
Figure 79. Middle East & Africa Blood Cancer Drugs Consumption Market Share by Application in 2019
Figure 80. Egypt Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 81. Egypt Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 82. South Africa Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 83. South Africa Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 84. Israel Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. Israel Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. Turkey Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. Turkey Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. GCC Countries Blood Cancer Drugs Consumption Growth 2015-2020 (K Units)
Figure 89. GCC Countries Blood Cancer Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. Global Blood Cancer Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 91. Global Blood Cancer Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 92. Americas Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 93. Americas Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 94. APAC Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 95. APAC Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 96. Europe Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 97. Europe Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 98. Middle East & Africa Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 99. Middle East & Africa Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 100. United States Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 101. United States Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 102. Canada Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 103. Canada Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 104. Mexico Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 105. Mexico Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 106. Brazil Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 107. Brazil Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 108. China Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 109. China Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 110. Japan Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 111. Japan Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 112. Korea Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 113. Korea Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 114. Southeast Asia Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 115. Southeast Asia Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 116. India Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 117. India Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 118. Australia Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 119. Australia Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 120. Germany Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 121. Germany Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 122. France Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 123. France Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 124. UK Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 125. UK Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 126. Italy Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 127. Italy Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 128. Russia Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 129. Russia Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 130. Spain Blood Cancer Drugs Consumption 2021-2025 (K Units)
Figure 131. Spain Blood Cancer Drugs Value 2021-2025 ($ Millions)
Figure 132. Egypt Blood Cancer Drugs Consumption 2021-2025 (K Units)
  • (Post-pandemic Era) - Global Smoking Cessation Products Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 27-Nov-2020        Price: US 3620 Onwards        Pages: 102
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Keyhole Limpet Hemocyanin (KLH) Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 27-Nov-2020        Price: US 3620 Onwards        Pages: 107
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Erythropoietin Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 27-Nov-2020        Price: US 3620 Onwards        Pages: 103
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Physiological Sea Water Nasal Spray Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 27-Nov-2020        Price: US 3620 Onwards        Pages: 117
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Herbal Oil Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 27-Nov-2020        Price: US 3620 Onwards        Pages: 114
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Excipients Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 27-Nov-2020        Price: US 3620 Onwards        Pages: 104
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Cetrimide Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 27-Nov-2020        Price: US 3620 Onwards        Pages: 107
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Smoking Cessation Products Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
    Published: 27-Nov-2020        Price: US 3650 Onwards        Pages: 107
    Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly opt......
  • (Post-pandemic Era) - Global Keyhole Limpet Hemocyanin (KLH) Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
    Published: 27-Nov-2020        Price: US 3650 Onwards        Pages: 102
    Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly opt......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs